EOS imaging (FR 0011191766 – EOSI) the pioneer in 2D/3D orthopaedic medical imaging today announces its consolidated full-year results for the year ended 31 December 2011. To learn more

The Ecole de Technologie Superieure (ETS - Montreal) named EOS imaging Partner of Excellence 2012 in technology transfer during the annual tribute ceremony in research-innovation that took place last March 20th. To learn more

Interview from Dr. Suken Shah, the Chief of Nemours Alfred I. duPont Hospital for Children’s Spine and Scoliosis Center (USA) “This is clearly the biggest advance in imaging that we’ve had for the spine I would say since the advent of x-rays in 1890”. To learn more

EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announces its consolidated revenue for the financial year to 31 December 2011. Please follow this link

Remarkable success of EOS imaging’s IPO, which raised 38 million euros at the upper end of the offering bracket on the NYSE Euronext regulated market in Paris. To learn more about this IPO , please follow this link

Within the framework of its planned IPO on the regulated market of NYSE Euronext in Paris, EOS imaging announces the registration of its “document de base” by the Autorité des Marchés Financiers. To learn lore about this IPO, please follow this link (you will be redirected to the french version of the website).

The UK’s National Institute for Health and Clinical Excellence (NICE) publishes diagnostic guidance encouraging the use of the EOS 2D/3D imaging system in specialist research settings

EOS ultra-low-dose 2D|3D orthopedic imaging system to be installed at major US institutions: Barnes-Jewish Hospital, New York University, University of Iowa

CAMBRIDGE, Mass., and PARIS, Sept. 15, 2010 — EOS imaging (www.eos-imaging.com) announced today that it is retiring the corporate name ‘biospace med’ and will now officially be known as ‘EOS imaging’, effective immediately.